SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · BioNTech announced the appointment of Guido Oelkers as CEO, effective…

BioNTech SE · 6-K filed Aug 3, 2026 at 06:54 ET

At the news

NEUTRALIMPACT 3/10

6-K filed Aug 3, 2026 at 06:54 ET

BioNTech announced the appointment of Guido Oelkers as CEO, effective by February 1, 2027, succeeding co-founder Prof. Ugur Sahin. Oelkers joins from Sobi with a track record of scaling biopharma operations. The filing signals a planned leadership transition as the company focuses on its late-stage oncology pipeline; no financial data or guidance was provided.

  • Guido Oelkers appointed CEO, to take office by February 1, 2027
  • Oelkers succeeds co-founder Prof. Ugur Sahin, who will transition to lead a new independent company with CMO Prof. Özlem Türeci
  • Search for a successor CMO is ongoing
  • Oelkers previously served as CEO of Sobi (2017-2026), where revenues more than quadrupled

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access